Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Table 5 Responder status for primary PRO measures from baseline to long-term follow-up visits

Primary PRO measure	Time point from baseline of the ATLAS study
	Week 36	Week 52	Week 76	Week 104	Week 128	Week 156
SF-36 PCS responder, ≥ 3-point decrease from baseline
n	^b	265	263	255	229	227
Responders, n (%)	^b	201 (75.8)^a	197 (74.9)^a	204 (80.0)^a	182 (79.5)^a	186 (81.9)^a
BASFI responder, ≥ 21% reduction from baseline
n	278	274	270	261	242	236
Responders, n (%)	203 (73.0)^a	208 (75.9)^a	211 (78.1)^a	210 (80.5)^a	195 (80.6)^a	193 (81.8)^a
ASQOL responder, ≥ 1.8-point reduction from baseline
n	^b	274	270	263	242	236
Responders, n (%)	^b	211 (77.0)^a	212 (78.5)^a	213 (81.0)^a	193 (79.8)^a	188 (79.7)^a

^aP < 0.001; chi-square test for equal proportions was performed.
^bMeasure not assessed at this time point.
ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASFI = Bath AS Functional Index; PCS = Physical Component Summary; PRO = patient-reported outcome; SF-36 = Short Form-36 Health Survey.

ISSN: 1478-6362